Phacilitate Leaders Forum

Phacilitate Leaders Europe Agenda 2018

Loading

Investment panel discussion: Constructing the perfect biotech: how can the ATMP biotech industry attract European, US and Asian investment?

11-Sep-2018
Joined Plenary – Navigating the path to commercialisation of ATMPs in Europe: funding, patient access and pricing and reimbursement
  • European vs US investment. Should biotech strategies change depending on the region they are seeking investment?
  • Recognising a gem in a crowded market. What do you look for in a biotech when investing in ATMP’s?
  • Constructing mutually beneficial partnership strategies between investors and biotechs
  • What’s the next big investment opportunity in ATMPs?
  • How can you make your organisation more appealing to investors
  • How soon is too soon for an IPO?
Speakers
Dmitry Kuzmin, Managing Partner - 4BIO Capital
Jasper Bos, Vice President and Head of Healthcare - Merck Ventures
Madhusudan Peshwa, CTO, Global Cell Therapy - GE Healthcare
Maina Bhaman, Partner - Sofinnova Partners
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd